Insights Corner

NASDAQ: ABVC

Insights Corner

Indian Talent in Taiwan

Indian Talent in Taiwan 150 150 ABVC

Lots of Indians work and study in Taiwan! Dr. Priya is visiting some students and professionals currently working in Taiwan to see how they feel about their lives here. This episode highlights ABVC’s CEO Uttam Patil and some of our hardworking colleagues in our Taiwan office. https://www.youtube.com/watch?v=xLBStpD5BAI

All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504

All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504 150 150 ABVC

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine 150 150 Press Release

FREMONT, CA, March 19, 2024 ABVC BioPharma Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine. This recognition is a testament to Dr. Patil’s outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company’s prospects, so he owns stock options without claiming a salary. Within his first year as the Company’s CEO, the Company saw a rise in the stock price of its common…

A Natural Approach to Alleviate Depression in Cancer Patients with Dr. Scott Irwin

A Natural Approach to Alleviate Depression in Cancer Patients with Dr. Scott Irwin 1858 976 ABVC

https://www.youtube.com/watch?v=QZ754OpWC7E In this video we talk wit Dr. Scott Irwin from Cedar-Sinai Medical Center. He shares insights on how we use a natural and herbal way to treat Depression in Cancer Patients. Scott A. Irwin, MD, PhD, FCLP, FAPA is professor of Psychiatry. He is currently the Director of the Patient and Family Support Program at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. His pioneering work involves exploring the potential of natural and herbal remedies in addressing the complex emotional challenges faced by individuals battling cancer. In this video he talks about his work with ABVC during the Phase I Clinical…

|ABVC BioPharma on McNallie Money | Best Biopharmaceutical Stocks Now

|ABVC BioPharma on McNallie Money | Best Biopharmaceutical Stocks Now 150 150 Russ Jaimes

https://www.youtube.com/watch?v=LbyWDe2wmW4& Have you seen this? ABVC has been featured in a recent video on McNallie Money. In this video, McNallie dives deep into our website and our pitch deck. We’re excited to see others recognizing the work of our doctors and scientist. It was great reading some positive comments on the video: @gilbertapicella2652 – It’s great to see ABVC BioPharma’s dedication to tackling various diseases and conditions through their extensive pipeline.- @jacentaschwartzbach5246 – ABVC BioPharma seems to be at the forefront of developing innovative solutions to address unmet medical needs. Exciting times ahead! @shawnlocke8904 – Interesting and creative approach by…

Summer 2024 Investor Presentation

View the latest product information, status updates, financial information, and more.

SAFE HARBOR STATEMENT

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Investor Considerations

  • Strong portfolio of medicines and medical devices addresses wide range of disorders.
  • In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
  • MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
  • Botanical expertise leads to medicines with fewer side effects.
  • Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
  • Business model designed to minimize burn rate.
  • Less than 30 million shares outstanding.

BACKGROUND

Leadership Team

NASDAQ: ABVC

Latest News

THERAPEUTIC FOCUS

Retinal Vitrectomy

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM